-Reported positive results from EMERALD-1 phase 2a trial of MORF-057 in ulcerative colitis - -Enrollment on target in EMERALD-2 phase 2b global randomized trial of MORF-057 in UC- .
Marla Dubinsky, MD, discusses the use of segmental intestinal ultrasound to address screen failure associated with the SES-CD in clinical trials and for detecting transmural healing.
Our December 2023 Gastroenterology Month in Review features a pair of American Gastroenterological Association guidelines and articles from the fourth installment of Qazi Corner.
The guideline was developed by a multidisciplinary panel and consists of 11 conditional recommendations for the use of biomarkers in the management of Crohn disease.
Ustekinumab is currently the only anti-interleukin therapy approved for the treatment of ulcerative colitis, but given the superior performance of risankizumab in CD patients, it will be interesting to see data regarding its efficacy in UC.